As the hospital continues to expand its capabilities to treat COVID-19 patients, SGS’s Life Sciences team is offering the use of its Clinical Pharmacology Unit (CPU) should more beds be required. The Unit is located within the hospital and is equipped with 88 beds, spread over 4 sub-units of 20-24 beds.
In addition, the team are all on stand-by to work with their colleagues at ZNA Hospitals as required, whether in nursing, medical or logistic roles.
SGS has also donated Personal Protective Equipment (PPE), including 1,100 masks and 21,000 gloves to ZNA.
Annick van Riel, Director Phase 1 Unit, SGS, said: “We are pleased to be in a position to donate PPE and materials, to be able to offer increased bed capacity within the hospital and to bring additional hands on deck capable of supporting our hospital colleagues in their battle to save lives and defeat this relentless pandemic.
“We want to extend our thanks to members of our team and colleagues who have willingly volunteered their experience and expertise to support the local community at this very challenging time.”
SGS has a wealth of expertise in First-In-Human studies, viral challenge testing, biosimilars and complex PK/PD studies, with a therapeutic focus on infectious diseases, vaccines, and respiratory.
On April 28, 2020, SGS will hold a webinar to explore the potential of CHIM, COVID-19 regulatory considerations, working with regulators and how to accelerate your pipeline, presented by our experts.
“COVID-19 human challenge trials – what will be the regulatory considerations?”
For further information, please contact:
Global Marketing Manager – Life Sciences
m: +44 7889 939 512
SGS is the world's leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 94,000 employees, SGS operates a network of over 2,600 offices and laboratories around the world.